Condition: Solid Tumors · Non-Small Cell Lung Cancer · Colorectal Cancer · Sponsor: Hansoh BioMedical R&D Company
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
This description comes directly from the study's public registry record.
Xiaowei Yan · 13061877102 · yanxw@hspharm.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06621563